Alkahest

Aging therapy using blood components

Also Clin2 Parkinson's, Clin1 inflammatory disease; AKST/GRF 6019/6021 2 trials Clin2 Alzheimer's, Clin2 Parkinson's, Clin2 postoperative recovery; AKST1210 Clin2 cognitive impairment from end stage renal disease; undisclosed programs RD undisclosed

Alkahest is developing treatments for neurodegenerative and age-related diseases. Many proteins that increase or decrease with age can be identified in the blood plasma. Alkahest is characterizing these proteins, known as chronokines, to create therapeutics to slow down or reverse age-related diseases. In particular, Alkahest is interested in chronokines involved in promoting restorative biological processes or pathological degenerative processes as therapeutic targets. Target identification follows the traditional pharmaceutical method, supplemented with Alkahest’s highly selected and refined plasma fractions. Using this approach, Alkahest has many product candidates in Phase 1 & 2 clinical trials.